Home > Healthcare > Medical Devices > Diagnostic Devices > Influenza Diagnostic Tests Market

Influenza Diagnostic Tests Market Trends

Report ID: GMI4242
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Influenza Diagnostic Tests Market Trends

Rising advancements in influenza diagnostic tests intended to improve the speed, accuracy, and efficiency in the detection of influenza viruses will spur the business growth.

The adoption of molecular diagnostics technique, particularly polymerase chain reaction (PCR) technology, have significantly enhanced the sensitivity and specificity of influenza diagnostic tests. Real-time PCR technologies allow for the rapid and accurate detection of influenza virus genetic material, enabling early diagnosis and effective management.
Moreover, technological progress has led to the development of multiplex assays that can simultaneously detect multiple respiratory pathogens, including different strains of influenza viruses. These assays enhance the efficiency of testing and provide comprehensive information, aiding in the differential diagnosis of respiratory infections.
These advancements not only enhance the accuracy and efficiency of influenza diagnostic tests but also contribute to a more robust and adaptable diagnostic ecosystem. Thus, technological advancements in influenza diagnostic tests are expected to drive the market development.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The influenza diagnostic tests market was valued at around USD 2.1 billion in 2022 and is estimated to reach over USD 3.9 billion by 2032, backed by the growing prevalence of influenza, rising demand for rapid diagnostic tests, and increase in R&D activities.

The traditional diagnostic test segment was valued at around USD 1.4 billion in 2022 and is expected to exhibit a robust growth trend through 2032, owing to their ease of use, quick results, and cost-effectiveness.

The U.S. influenza diagnostic tests market is anticipated to expand at a notable pace to reach more than USD 1.2 billion by 2032, attributed to robust healthcare infrastructure, R&D initiatives, and high disease burden, and seasonal outbreaks.

F. Hoffmann-La Roche Ltd, Abbott, Becton, Dickinson, and Company, Coris BioConcept, DiaSorin SpA, Meridian Bioscience Inc., Quidel Corporation, Sekisui Diagnostics, Thermo Fischer Scientific Inc., and Hologic Inc.